Objective：To explore the effect of cinobufacini com bined with the chemotherapy of paclitaxel and cisplatin(TP regimen)on the immune function of senile patients with advanced non-sm all cell lung cancer(NSCLC)and exp lore the factors associated with prognosis.Methods：Divided 77 cases of senile patients with advanced NSCLC into the com bined treatment group and the control group according to the random num ber table method.The com bined treatment group adopted cinobufacini com bined with TP regimen for treatment，and the control group applied TP regimen for treatment.Follow ed up and observed the changes of relevant indicators about peripheral blood immune function and evaluated the factors associated with prognosis.Results：After treatment of two courses，there was no significant difference being found in the comparison of the immune function indicators in the control group before and after treatment( P ＞ 0.05).After treatment，compared the immune function indicators in the com bined treatment group with those before treatment and those in the control group after treatment，differences were significant( P ＜0.05).After treatment，the effective rate of pain relief in the com bined treatment group was 71.1%，higher than that of 48.7%in the controlgroup，the difference being significant( P ＜0.05).The incidence of adverse reactions including leukopenia， neutropenia， throm bocytopenia and gastrointestinal reactions in the com bined treatment group was lower than that in the control group( P ＜0.05).After treatment，the number of patients in the com bined treatment group whose KPS score increased by over 20%and over 10%was larger than that in the control group，thedifference being significant( P ＜0.05).After conducting a 1-year follow-up and univariate Kaplan-Meier analysis of the factors associated with prognosis in patients who completed treatment，the 1-year survival rate in the com bined treatment group was 80.5%，higher than that of 78.3%in the control group，there being no significance in the difference( P ＞0.05).The analysis of the factors associated with prognosis indicated that gender，pathology and stage were not the factors that influence prognosis，there being no significance in the difference after Log-rank test( P ＞ 0.05).Before treatment，the KPS score，the com bination of chest w ater and group conditions were examined by Log-rank test，the difference being significant( P ＜0.05).Conclusion：The therapy of cinobufacinicombined with TP regimen can improve the immune function of the senile patients with advanced NSCLC， improve their quality of life，reduce the toxic and side effects of chemotherapy， and contribute to the improvement of the long-term survival of patients.